MONMOUTH JUNCTION, N.J., Oct. 5 /PRNewswire/ -- Transave, Inc., a biopharmaceutical company developing drugs for life-threatening lung diseases, today announced the appointment of Renu Gupta, M.D. as Executive Vice President of Development and Chief Medical Officer.
Dr. Gupta has more than 20 years of development, regulatory and senior management experience at such leading companies as Novartis, Bristol-Myers Squibb, Antigenics, and Covance, where she was involved in the development and approval of such leading drugs as Abelcet(R), Cefzil(R), Maxipime(R), Videx(R), and Diovan(R). In her new role, Dr. Gupta will lead all aspects of development and regulatory affairs for Transave’s robust pipeline of inhaled therapeutics.
“We believe Renu’s experience and track record of success developing and obtaining approval for drugs in infectious diseases and oncology will greatly expedite and facilitate the advancement of our lead programs in cystic fibrosis and lung cancer toward the market,” said Timothy G. Whitten, President and CEO of Transave.
Dr. Gupta joins Transave from Antigenics, Inc., where she was Senior Vice President of Development, advancing its immunotherapy and small molecule pipeline for Oncology and Infectious Diseases. Prior to that, she served at Novartis as Vice President and Head of U.S. Clinical Research and Development and Global Head of Cardiovascular, Metabolics, Endocrine and Gastroenterology Research. Dr. Gupta also spent two years at Covance as Vice President and Head of Medical, Safety and Therapeutics, and almost 10 years at Bristol-Myers Squibb, where she was responsible for clinical research, business development and global development and marketing strategy.
Dr. Gupta received her bachelor and medical degrees from the University of Zambia and completed her medical and post-doctoral training at Albert Einstein Medical Center and the University of Pennsylvania’s Children’s Hospital of Philadelphia. Her work has been published in leading peer-reviewed journals, including the Journal of Infectious Diseases, and she has been active in numerous relevant academic and professional societies such as the Infectious Disease Society of America and the American Academy of Pediatrics.
About Transave, Inc.
Transave is a privately-held biopharmaceutical company focused on the development of innovative, site-specific treatments for lung diseases. The company’s approach is based on its proprietary Sustained-release Lipid Inhaled Targeting (“SLIT(TM)”) technology designed to sustain release of active drugs in the lung’s microenvironment potentially enhancing the therapeutic benefits. The Company has two products in clinical development focused on pulmonary infections and lung cancer: SLIT(TM) Amikacin, for Pseudomonas aeruginosa infections for cystic fibrosis, and SLIT(TM) Cisplatin, for lung and ovarian cancer.
Inhaled SLIT(TM) drug formulations utilize lipid constituents endogenous to the lung to make biocompatible, inhalable lipid/drug complexes that are well tolerated. This approach may help to reduce or eliminate toxicities or dosing problems associated with systemic drugs through localized drug administration and controlled release in the lung and create new or improved product profiles for already well-characterized drugs. For more information about Transave’s technology and development programs, visit www.transaveinc.com .
Transave, Inc.
CONTACT: Andrew J. Gorman, Ph.D., Vice President, Business Development ofTransave, Inc., +1-732-438-9434, or agorman@transaveinc.com
Web site: http://www.transaveinc.com/
